MX335945B - Composicion antifungica novedosa. - Google Patents

Composicion antifungica novedosa.

Info

Publication number
MX335945B
MX335945B MX2013009245A MX2013009245A MX335945B MX 335945 B MX335945 B MX 335945B MX 2013009245 A MX2013009245 A MX 2013009245A MX 2013009245 A MX2013009245 A MX 2013009245A MX 335945 B MX335945 B MX 335945B
Authority
MX
Mexico
Prior art keywords
antifungal composition
novel antifungal
composition
diol
nail
Prior art date
Application number
MX2013009245A
Other languages
English (en)
Other versions
MX2013009245A (es
Inventor
Åke Lindahl
Original Assignee
Moberg Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45581892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX335945(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Moberg Pharma Ab filed Critical Moberg Pharma Ab
Publication of MX2013009245A publication Critical patent/MX2013009245A/es
Publication of MX335945B publication Critical patent/MX335945B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporciona una composición farmacéutica para el tratamiento de infección fúngica de la uña que comprende un compuesto de alilamina antifúngico presente en una cantidad de aproximadamente 10%, un ácido orgánico o un éster del mismo, un diol y un agente de secuestro en donde la composición farmacológica se encuentra esencialmente libre de agua.
MX2013009245A 2011-02-11 2012-02-10 Composicion antifungica novedosa. MX335945B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1150107 2011-02-11
PCT/EP2012/052327 WO2012107565A1 (en) 2011-02-11 2012-02-10 Novel antifungal composition

Publications (2)

Publication Number Publication Date
MX2013009245A MX2013009245A (es) 2013-12-09
MX335945B true MX335945B (es) 2016-01-04

Family

ID=45581892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009245A MX335945B (es) 2011-02-11 2012-02-10 Composicion antifungica novedosa.

Country Status (24)

Country Link
US (3) US8952070B2 (es)
EP (1) EP2672962B1 (es)
JP (1) JP5883886B2 (es)
KR (1) KR101647545B1 (es)
CN (2) CN109453150A (es)
AU (1) AU2012215383B2 (es)
BR (1) BR112013020456B1 (es)
CA (1) CA2826741C (es)
CY (1) CY1116275T1 (es)
DK (1) DK2672962T3 (es)
ES (1) ES2535827T3 (es)
HR (1) HRP20150507T1 (es)
IL (1) IL227765A (es)
ME (1) ME02152B (es)
MX (1) MX335945B (es)
PL (1) PL2672962T3 (es)
PT (1) PT2672962E (es)
RS (1) RS53982B1 (es)
RU (1) RU2587064C2 (es)
SG (1) SG192615A1 (es)
SI (1) SI2672962T1 (es)
SM (1) SMT201500154B (es)
WO (1) WO2012107565A1 (es)
ZA (1) ZA201305891B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952070B2 (en) 2011-02-11 2015-02-10 Moberg Pharma Ab Antifungal composition
JP5815879B2 (ja) * 2012-08-30 2015-11-17 ▲華▼▲為▼終端有限公司Ｈｕａｗｅｉ Ｄｅｖｉｃｅ Ｃｏ．， Ｌｔｄ． 中央処理装置を制御する方法および装置
CA2998895A1 (en) * 2015-10-07 2017-04-13 Exodos Life Sciences Lp Topical antifungal compositions
US10543276B2 (en) 2016-08-08 2020-01-28 Marlinz Pharma, LLC Topical compositions
US10251858B1 (en) 2016-08-08 2019-04-09 Marlinz Pharma, LLC Composition for treating fungal infections in nails
EP3292758A1 (en) 2016-09-07 2018-03-14 Rottapharm S.p.A. Antimicrobial composition comprising a carboxylic acid and two diols
WO2019206389A1 (en) * 2018-04-27 2019-10-31 Unigroup Aps Kit of parts for nail fungus
US11576920B2 (en) 2019-03-18 2023-02-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CA3201760A1 (en) * 2020-12-08 2022-06-16 Torbjorn Warnheim Treatment regimen for onchyomycosis using allylamine antifungal compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
DE4337945A1 (de) * 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
WO1999009997A1 (en) 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
AUPP146598A0 (en) * 1998-01-21 1998-02-12 Health And Hygiene International Pty Ltd Fruit and vegetable wash
DE19921794A1 (de) 1999-05-11 2000-11-23 Hexal Ag Neue pharmazeutische Zusammensetzung
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
JP4803511B2 (ja) * 2000-08-25 2011-10-26 株式会社ポーラファルマ 抗真菌医薬組成物
CN1678277B (zh) * 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
EP1545619B1 (en) * 2002-09-05 2008-01-23 Galderma S.A. Solution for ungual application
JP5059408B2 (ja) * 2004-08-05 2012-10-24 久光製薬株式会社 爪用外用剤
US20060078599A1 (en) * 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue
JP4992181B2 (ja) 2004-12-28 2012-08-08 大正製薬株式会社 外用剤組成物
WO2006103638A2 (en) 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
CN1939539A (zh) 2005-09-29 2007-04-04 瑞士商拜欧伊果公司 疣、指甲疾病、及指甲保养用之局部配方
US20080299060A1 (en) 2006-01-02 2008-12-04 Tlt Medical Ltd. Pharmaceutical Composition for the Treatment of Nail Diseases
US20070243222A1 (en) * 2006-02-03 2007-10-18 Carl Lawyer Fungicidal formulation and method of use
WO2007094999A2 (en) * 2006-02-13 2007-08-23 Stiefel Laboratories, Inc. Ungual antifungal compositions
US20080038219A1 (en) 2006-08-07 2008-02-14 Calgenex Corporation Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
WO2008152444A2 (en) * 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
US8052984B2 (en) * 2007-02-05 2011-11-08 Biophile Corporation, Ltd. Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages
US20080261986A1 (en) * 2007-03-30 2008-10-23 Friden Phillip M Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
MX2011000932A (es) * 2008-07-23 2011-05-19 Targeted Delivery Technologies Ltd Metodos para administrar formulaciones antifungicas topicas para el tratamiento de infecciones fungicas.
US8524258B2 (en) * 2008-12-22 2013-09-03 Johnson & Johnson Consumer Companies, Inc. Structured lotions
FR2942716B1 (fr) * 2009-03-06 2011-04-15 Galderma Res & Dev Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle
CA2764236A1 (en) * 2009-08-13 2011-02-17 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail
WO2011079234A2 (en) * 2009-12-23 2011-06-30 Nuvo Research Inc. Highly permeating terbinafine formulation
WO2012017371A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, clobetasole propionate, terbinafine hydrochloride and a process to make it
US8952070B2 (en) 2011-02-11 2015-02-10 Moberg Pharma Ab Antifungal composition

Also Published As

Publication number Publication date
IL227765A (en) 2016-09-29
HK1190944A1 (en) 2014-07-18
SMT201500154B (it) 2015-09-07
CN103384518B (zh) 2018-10-26
CN109453150A (zh) 2019-03-12
US20150250878A1 (en) 2015-09-10
DK2672962T3 (en) 2015-04-20
PL2672962T3 (pl) 2015-08-31
KR20140025341A (ko) 2014-03-04
SI2672962T1 (sl) 2015-06-30
CY1116275T1 (el) 2017-02-08
MX2013009245A (es) 2013-12-09
ZA201305891B (en) 2015-06-24
CN103384518A (zh) 2013-11-06
HRP20150507T1 (hr) 2015-06-19
IL227765A0 (en) 2013-09-30
AU2012215383B2 (en) 2016-06-09
RU2587064C2 (ru) 2016-06-10
US20140031430A1 (en) 2014-01-30
KR101647545B1 (ko) 2016-08-10
ES2535827T3 (es) 2015-05-18
JP5883886B2 (ja) 2016-03-15
SG192615A1 (en) 2013-09-30
EP2672962A1 (en) 2013-12-18
ME02152B (me) 2015-10-20
US9561279B2 (en) 2017-02-07
EP2672962B1 (en) 2015-03-25
US8952070B2 (en) 2015-02-10
WO2012107565A1 (en) 2012-08-16
US20170258914A1 (en) 2017-09-14
RS53982B1 (sr) 2015-10-30
RU2013136147A (ru) 2015-03-20
CA2826741C (en) 2016-03-29
BR112013020456B1 (pt) 2020-01-21
PT2672962E (pt) 2015-05-25
JP2014508146A (ja) 2014-04-03
BR112013020456A2 (pt) 2016-10-18
CA2826741A1 (en) 2012-08-16
AU2012215383A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
MX2013009245A (es) Composicion antifungica novedosa.
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
MX336381B (es) Boronatos como inhibidores de arginasa.
MD20140009A2 (ro) Compuşi pentru tratamentul adicţiei
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GEP20146125B (en) Aminopyrimidines as syk inhibitors
CA2818925A1 (en) Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2010014041A (es) Una forma cristalina de posaconazol.
IN2014CN03307A (es)
DOP2012000011A (es) Formulacion farmaceutica
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
BR112013006362A2 (pt) uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
IN2014DN01619A (es)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EP2666773A8 (en) Organic amine salts of azilsartan, preparation method and use thereof
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
PH12015500047A1 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo